These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20942646)

  • 1. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
    Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
    J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
    Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
    J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
    Pockros PJ; Jensen D; Tsai N; Taylor R; Ramji A; Cooper C; Dickson R; Tice A; Kulkarni R; Vierling JM; Lou Munson M; Chen YC; Najera I; Thommes J;
    Hepatology; 2013 Aug; 58(2):514-23. PubMed ID: 23359491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
    Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
    De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
    J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
    Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
    Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.
    Rutter K; Scherzer TM; Beinhardt S; Kerschner H; Stättermayer AF; Hofer H; Popow-Kraupp T; Steindl-Munda P; Ferenci P
    Antivir Ther; 2011; 16(8):1327-33. PubMed ID: 22155914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.
    Bronowicki JP; Pol S; Thuluvath PJ; Larrey D; Martorell CT; Rustgi VK; Morris DW; Younes Z; Fried MW; Bourlière M; Hézode C; Reddy KR; Massoud O; Abrams GA; Ratziu V; He B; Eley T; Ahmad A; Cohen D; Hindes R; McPhee F; Reilly B; Mendez P; Hughes E
    Antivir Ther; 2013; 18(7):885-93. PubMed ID: 23804631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions.
    Quiles-Pérez R; Muñoz-de-Rueda P; Maldonado AM; Martín-Álvarez A; Quer J; Salmerón J
    J Med Virol; 2014 Nov; 86(11):1886-97. PubMed ID: 25091333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
    Nicot F; Alric L; Barange K; Métivier S; Dramard JM; Combis JM; Castan B; Meurisse JJ; Payen JL; Garipuy D; Desmorat H; Peron JM; Thebault S; Morin T; Renou C; Barel P; Guerin B; Imbert Y; Sire S; Sauné K; Chatelut E; Izopet J
    J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
    Mihm U; Hofmann WP; Welsch C; Polta A; Lengauer T; Zeuzem S; Sarrazin C; Herrmann E
    J Viral Hepat; 2010 Mar; 17(3):217-21. PubMed ID: 19758279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
    Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
    Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
    Le Pogam S; Yan JM; Chhabra M; Ilnicka M; Kang H; Kosaka A; Ali S; Chin DJ; Shulman NS; Smith P; Klumpp K; Nájera I
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5494-502. PubMed ID: 22869576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
    Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L
    Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.
    Tong X; Li L; Haines K; Najera I
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3105-14. PubMed ID: 24637689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
    McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
    Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.